VerifyDx Genomic Cancer Tests
VerifyDx Prostate Cancer Test
Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society’s estimates there will be about 180,890 new cases of prostate cancer in the United States for 2016. Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it. In fact, more than 2.9 million men in the United States who have been diagnosed with prostate cancer at some point are still alive today.
Clinical and Pathological Challenges to Prostate Diagnosis
The current risk assessment methods that urologists and pathologists use today aren't sensitive enough to distinguish a highly metastatic tumor from one that might be slow growing. When there is a lack of confidence in the method of assessment, the conservative route is often offered as the best course of treatment. That is why we developed the VerifyDx genomic test.
Why Genomic Tests Offer Better Insight into Prostate Cancer
Genomic tests offer a much better picture of what is going on inside the tumor cells. By interrogating specific genomic markers urologists and pathologists are able to see how aggressive the cancer may become. We can do this by looking at specific biomarkers. Some biomarkers cause the cancer to grow rapidly, other markers are there to suppress the cancer. By looking at the expression levels of all of these different markers we are able to better predict cancer aggressiveness. With a more accurate view of the tumor progression, urologists are better able to personalize the cancer treatment.